What happened
UCB, a biopharmaceutical group, has partnered with Cradle, an AI-based protein design platform, to apply artificial intelligence in antibody discovery. The collaboration will cover the discovery chain, from the generation of the first active molecules to the optimization of lead molecules and preparation for the preclinical phase. The agreement complements UCB's computing capabilities, its own antibody discovery platform, and its network of technology and research partners.
The partnership between UCB and Cradle will apply AI in antibody discovery, covering the discovery chain from the generation of the first active molecules to the optimization of lead molecules and preparation for the preclinical phase.
The agreement complements UCB's computing capabilities, its own antibody discovery platform, and its network of technology and research partners.
The collaboration relies on a back-and-forth between computation and experimentation, with experimental results continuously feeding models specific to each program, a cumulative learning loop referred to as “lab-in-the-loop”.
Alistair Henry, Chief Scientific Officer of UCB, presents AI as a scientific force multiplier that strengthens human expertise, while Stef van Grieken, Chief Executive Officer and co-founder of Cradle, believes that AI will have its greatest impact on biologics R&D when it can be deployed beyond individual experiments or programs.
The partnership aims to provide UCB's scientists with a common platform to apply AI to more programs, more modalities, and more complex engineering challenges.
Source details: ideal-investisseur.fr
Why it matters
This partnership has the potential to improve the design of antibodies, which are crucial in the treatment of serious diseases. The use of AI in this process can lead to faster and more efficient discovery of new molecules, potentially leading to better treatments for patients. Additionally, this collaboration demonstrates the growing interest in applying AI in the biopharmaceutical industry.
This partnership has the potential to improve the design of antibodies, which are crucial in the treatment of serious diseases.
The use of AI in this process can lead to faster and more efficient discovery of new molecules, potentially leading to better treatments for patients.
This collaboration demonstrates the growing interest in applying AI in the biopharmaceutical industry.
The partnership between UCB and Cradle has the potential to lead to the development of new treatments for serious diseases, such as cancer and autoimmune disorders.
The use of AI in antibody discovery can also lead to the development of more targeted and effective treatments, reducing the risk of side effects and improving patient outcomes.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
What to watch next
The impact of this partnership on the development of new treatments for serious diseases, the potential for faster and more efficient discovery of new molecules, and the growing interest in applying AI in the biopharmaceutical industry.
The impact of this partnership on the development of new treatments for serious diseases.
The potential for faster and more efficient discovery of new molecules.
The growing interest in applying AI in the biopharmaceutical industry.
The potential for this partnership to lead to the development of more targeted and effective treatments.
The potential for this partnership to improve patient outcomes and reduce the risk of side effects.